COC protocol
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | COC Protocol (Care Oncology Clinic Protocol) |
| Overview | The COC Protocol is an adjunctive metabolic therapy that combines four repurposed drugs to target glioblastoma’s metabolic vulnerabilities. Retrospective studies suggest potential survival benefits, but more clinical research is needed to confirm its efficacy and optimize its use alongside conventional treatments. |
| FDA Approval | No (Individual drugs are FDA-approved for other conditions; the combination is not FDA-approved for cancer treatment) |
| Used for | Adjunctive metabolic therapy for glioblastoma and other cancers |
| Clinical Trial Phase | Clinical use with retrospective analysis; some components in clinical trials for cancer |
| Clinical Trial Explanation | The COC Protocol is being evaluated for its impact on cancer progression, particularly in glioblastoma. Retrospective studies suggest potential survival benefits, and individual drugs within the protocol have been studied for their anti-cancer effects. |
| Common Side Effects | Varies by drug; includes gastrointestinal upset, fatigue, liver enzyme changes, and potential interactions with other treatments |
| OS without | Not specified |
| OS with | Some retrospective analyses indicate extended survival in glioblastoma patients using COC Protocol alongside standard treatments. |
| PFS without | Not specified |
| PFS with | Preliminary data suggests a potential role in slowing glioblastoma progression, but more studies are needed. |
| Usefulness Rating | 4.5 |
| Usefulness Explanation | The COC Protocol targets cancer metabolism through a multi-drug regimen, aiming to enhance standard treatments and reduce recurrence. Retrospective analyses suggest improved outcomes in glioblastoma patients, but randomized clinical trials are needed for definitive proof.Property "Has Usefulness Explanation" (as page type) with input value "The COC Protocol targets cancer metabolism through a multi-drug regimen, aiming to enhance standard treatments and reduce recurrence. Retrospective analyses suggest improved outcomes in glioblastoma patients, but randomized clinical trials are needed for definitive proof." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process. |
| Toxicity Level | 3 |
| Toxicity Explanation | Each drug in the protocol has an established safety profile, but the combination requires careful monitoring for potential interactions, liver function impact, and side effects. Coordination with an oncologist is advised to minimize risks. |
Notes: The COC Protocol is a metabolic-based treatment strategy designed to target multiple cancer pathways using repurposed drugs. It typically includes Metformin, Atorvastatin, Doxycycline, and Mebendazole, each chosen for its ability to disrupt cancer metabolism and inhibit tumor growth.
Glioblastoma is a highly aggressive cancer with poor prognosis, and metabolic approaches like the COC Protocol offer a novel angle by targeting cancer’s energy production and survival mechanisms. While it has shown promise in retrospective analyses, ongoing research is required to establish its efficacy through clinical trials.
Links: * [Care Oncology Clinic official site](https://www.careoncology.com/)
- [ClinicalTrials.gov studies related to metabolic therapy in glioblastoma](https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=metabolic+therapy&cntry=&state=&city=&dist=)
- [Study on the role of metabolic interventions in glioblastoma](https://www.ncbi.nlm.nih.gov/pubmed/)
- [Metabolic targeting in glioblastoma: Review of repurposed drugs](https://www.mdpi.com/journal/pharmaceuticals)
From Ben Williams Book: Not specified
Loading comments...
